# K080766 510(k) SUMMARY

VIDAS® RUB IgG Assay

# DEC 2 3 2008

A. Submitter Information Submitter's Name: Address: Contact Person: Phone Number: Fax Number: Date of Preparation:

bioMérieux, Inc.   
595 Anglum Road   
Hazelwood, MO 63042   
Sandra Perreand   
Sr. Director, North American Regulatory Affairs 314-731-8594   
314-731-8689   
December 2008

B. Device Name Trade Name: Common Name: Classification Name:

VIDAS® RUB IgG Assay   
Rubella IgG Antibody   
Enzyme Linked Immunoabsorbent Assay, Rubella

Predicate Device Name Trade Name:

AxSYM Rubella IgG Antibody Assay

# D.Device Description

The assay principle combines a 2-step enzyme immunoassay sandwich method with a final fluorescent ttionASlid hase ece $\{ \mathsf { S P R } ^ { \mathfrak { P } } \}$   
wTe an pre-dispensed in the sealed reagent strips.The individual kit components are described in detail o the following pages.

All theassay seps are performe autoatically by the instrumentThe reaction medium is cyc an out of the SPR several tmes.This operation enables the Rubella antigen fixed onto the interior wall o the SPR to capture the Rubella antibodies present in the sample.After dilution, the sample is incubated with the SPR.Rubella IgG antibodies present in the specimen bind to the Rubella antigen catng the interior of the SR.Unbound components are elminated during the prelminary wash step.

Asend incubation steis then performeusing alkaline phosphatase abeldmoncnal antihuma IgG antibodies (mouse), followed by a second wash step.

Duriefal detectn step,he substrat 4-Methy-belliferyl phosate iscycled in and out  he SPR. The conjugate enzyme catalyzes the hydrolysis of this substrate into a fluorescent product (4 Methyl-umbelliferone), the fluorescence of which is measured at $4 5 0 n m$

The intensity of the florescence s proportional to the concentrationoantibodies present in the sample. A tehessuutatialy alculat yhesten elatneal curve stored in memory, and then printed out.

# E. Intended Use

The VIDAS® RUB IgG (RBG) assay uses Enzyme Linked Fluorescent Assay (ELFA) technology on the VIDAS® automated instruments for the in vitro quantitative and qualitative measurement of IgG anodies ubella virus inuman serum.The VIDAS® RUB IgG assay is ntended as an aid i e determination of immune status to rubella. The performance of this device has not been established for screening of cord blood, or for neonatal samples. Likewise, performance characteristics of the assay have not been established for immunocompromised or immunosuppressed individuals.

# F. Technological Characteristics Summary

A general coparison f the similarits nd diffrences f the VIDAS RUB IGassay  the pricat device is presented in the table below.

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>VIDAS® RUB IgG Assay</td><td rowspan=1 colspan=1>Abbott&#x27;sAxSYM Rubella IgG Antibody Assay(K954045)</td></tr><tr><td rowspan=1 colspan=3>General Comparison</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The VIDAS® RUB IgG (RBG) assay usesEnzyme Linked Fluorescent Assay(ELFA) technology on the VIDASautomated instruments for the in vitroquantitative and qualitative measurementof IgG antibodies to rubella virus inhuman serum. The VIDAS® RUB IgGassay is intended as an aid in thedetermination of immune status to rubella.The performance of this device has notbeen established for screening of cordblood, or for neonatal samples. Likewise,performance characteristics of the assayhave not been established forimmunocompromised orimmunosuppressed individuals.</td><td rowspan=1 colspan=1>The AxSYM Rubella IgG assay is aMicroparticle Enzyme Immunoassay(MEIA) for the quantitative andqualitative measurement of IgGantibodies to rubella virus in humanserum or plasma (EDTA, heparin orsodium citrate) to aid in thedetermination of immune status torubella.</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum or plasma (EDTA, heparin orsodium citrate)</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>Rubella IgG</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Mouse monoclonal anti-human IgG</td><td rowspan=1 colspan=1>Goat anti-human IgG</td></tr><tr><td rowspan=1 colspan=1>Assay Principle</td><td rowspan=1 colspan=1>Two step antibody binding of Rubellaantibodies. An antigen is bound to a solidphase and anti-human IgG is in liquidform and is labeled with fluorescentcompound</td><td rowspan=1 colspan=1>Twostep antibody binding of Rubellaantibodies. An antigen is bound to asolid phase and anti-human IgG is inliquid form and is labeled withfluorescent compound</td></tr><tr><td rowspan=1 colspan=1>Automated</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>Assay Technique</td><td rowspan=1 colspan=1>Enzyme-linked fluorescent assay (ELFA)</td><td rowspan=1 colspan=1>Microparticle enzyme immunoassay(MEIA)</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>100 μL</td><td rowspan=1 colspan=1>180 μL</td></tr><tr><td rowspan=1 colspan=1>Traceability/Standardization</td><td rowspan=1 colspan=1>Master curve for each kit lot and eachcalibrator lot are traceable to the preparation of the World HealthOrganization (WHO) 1 InternationalRubella Reference Standard</td><td rowspan=1 colspan=1>Each calibrator lot is traceable to theWorld Health Organization (W.H.O.)2nd International Standard for Anti-Rubella Immunoglobulin</td></tr><tr><td rowspan=1 colspan=1>Measurement range</td><td rowspan=1 colspan=1>0 -400 IU/mL</td><td rowspan=1 colspan=1>0 - 500.0 IU/mL</td></tr></table>

# G. Performance Data

# Precision

F usig gten cs $( N = 2 4 0 )$ The repeatability (intra-run precision), inter-run precision, a $\zeta \lfloor S \rfloor ^ { \circled { \otimes } }$ EP5-A2 document

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Inter-runprecision</td><td rowspan=1 colspan=2>Between siteprecision</td><td rowspan=1 colspan=2>Total precision</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Meanconcentration IU/mL</td><td rowspan=1 colspan=1>Standarddeviation</td><td rowspan=1 colspan=1>CV(%</td><td rowspan=1 colspan=1>Standarddeviation</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>Standarddeviation</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>Standarddevation</td><td rowspan=1 colspan=1>CV((%)</td></tr><tr><td rowspan=1 colspan=1>Sample 1</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.84</td><td rowspan=1 colspan=1>10.8</td></tr><tr><td rowspan=1 colspan=1>Sample 2</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>10.2</td></tr><tr><td rowspan=1 colspan=1>Sample 3</td><td rowspan=1 colspan=1>29.8</td><td rowspan=1 colspan=1>1.46</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>2.62</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.14</td><td rowspan=1 colspan=1>10.6</td></tr><tr><td rowspan=1 colspan=1>Sample 4</td><td rowspan=1 colspan=1>154.6</td><td rowspan=1 colspan=1>10.58</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>18.49</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>21.30</td><td rowspan=1 colspan=1>13.8</td></tr></table>

# Clinical Performance

Th bVIASRUB

# Prospective populations

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Prospective Pregnant Women2/3 Consensus</td><td rowspan=1 colspan=4>Prospective General2/3 Consensus</td></tr><tr><td rowspan=1 colspan=1>VIDAS®</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Equiv</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Equiv</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>309</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>310</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>171</td></tr><tr><td rowspan=1 colspan=1>Equiv</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>319</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>325</td><td rowspan=1 colspan=1>173</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>179*</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>96.9% (309/319)</td><td rowspan=1 colspan=1>94.3-98.5</td><td rowspan=1 colspan=1>97.1% (170/175)</td><td rowspan=1 colspan=1>93.5 - 99.1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>66.7% (2/3)</td><td rowspan=1 colspan=1>9.4 - 99.2</td><td rowspan=1 colspan=1>66.7% (2/3)</td><td rowspan=1 colspan=1>9.4 - 99.2</td></tr></table>

\*One sample was defined as Qns (quantity not sufficient) and excluded from the analysis.

# Retrospective populations

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Retrospective Pregnant Women2/3 Consensus</td><td rowspan=1 colspan=4>Retrospective General2/3 Consensus</td></tr><tr><td rowspan=1 colspan=1>VIDAS®</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Equiv</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Equiv</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>179</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>179</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>169</td></tr><tr><td rowspan=1 colspan=1>Equiv</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>111</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>291*</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>92.7% (179/193)</td><td rowspan=1 colspan=1>88.1-96.0</td><td rowspan=1 colspan=1>92.3% (169/183)</td><td rowspan=1 colspan=1>87.5 - 95.8</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>100% (3/3)</td><td rowspan=1 colspan=1>29.2-100.0</td><td rowspan=1 colspan=1>100% (104/104)</td><td rowspan=1 colspan=1>96.5-100.0</td></tr></table>

\*Fi samples were defied as s (quantiy ot sufficient) and excludd from he analysis

# Pre-selected Pregnant Women Population

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Pre-selected Pregnant Women2/3 Consensus Method</td></tr><tr><td rowspan=1 colspan=1>VIDAS</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Equiv</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>Equiv</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>104</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>127*</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>92.0%(23/25)</td><td rowspan=1 colspan=1>74.0 - 99.0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>100% (102/102)</td><td rowspan=1 colspan=1>96.4 - 100.0</td></tr></table>

\*Two samples were defined as QNS (quantity not sufficient) and excluded from the analysis.

# H. Conclusion The VIDAS® RUB IgG Assay is substantially equivalent to Abbott Laboratories AxSYM Rubella IgG Antibody Assay.

The 510(k) summary includes only information that is also covered in the body of the 510(k). The summary does not contain any puffery or unsubstantiated labeling claims. The summary does not contain any raw data, i., contains only summary data.The summary does not contain any trade seet or confidential commercial information. The summary does not contain any patient identification information.

# DEC 23 2008

Sandra Perreand   
Sr. Director, N.A. Regulatory Affairs bioMérieux, Inc.   
595 Anglum Road   
Hazelwood, MO 63042

Re: K080766 Trade/Device Name: VIDAS® RUB IgG Assay Regulation Number: 21CFR $\ S 8 6 6 . 3 5 1 0$ Regulation Name: Rubella virus serological reagents Regulatory Class: Class II Product Code: LFX Dated: December 19, 2008 Received: December 22, 2008

Dear Ms. Perreand:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Sall atty

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# Enclosure

510(k) Number (if known): K080766

Device Name: VIDAS@ RUB IgG

Indications For Use:

The VIDAS® RUB IgG (RBG) assay uses Enzyme Linked Fluorescent Assay (ELFA) technology on the $V / \mathsf { D A S } ^ { \otimes }$ automated instruments for the in vitro quantitative and qualitative measurement of IgG antibodies to rubella virus in human serum. The VIDAS® RUB IgG assay is intended as an aid in the determination of immune status to rubella. The performance of this device has not been established for screening of cord blood, or for neonatal samples. Likewise, performance characteristics of the assay have not been established for immunocompromised or immunosuppressed individuals.

Prescription Use_ (21 CFR Part 801 Subpart D)

And/Or

![](images/790c0453641dfaf4ae3249fffa13845828bac9ab7e529c69da63b7929c6dbed0.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety